Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products in orthopedic, sports medicine and wound care markets announced today its financial results for the third quarter of 2013.
•Product revenue for the quarter rose to $6.9 million - up 220% from the third quarter of 2012.
Help employers find you! Check out all the jobs and post your resume.
